Mirna Therapeutics Inc. (NASDAQ:MIRN) shares traded down 13.4% on Tuesday . The company traded as low as $2.38 and last traded at $2.59, with a volume of 102,668 shares trading hands. The stock had previously closed at $2.99.

A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 18th. Oppenheimer Holdings Inc. lifted their price objective on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, August 16th. Citigroup Inc. downgraded shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $7.00 to $4.50 in a research report on Tuesday, August 16th. Leerink Swann downgraded shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $10.00 to $4.00 in a research report on Monday, August 15th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price objective on shares of Mirna Therapeutics in a research report on Friday, May 13th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $8.10.

The stock’s market capitalization is $52.09 million. The company’s 50-day moving average price is $3.88 and its 200 day moving average price is $4.27.

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.